114 related articles for article (PubMed ID: 7479230)
1. [Hypothermia during chemotherapy for lymphomas].
Gabryś K; Mazur G
Pol Arch Med Wewn; 1995 Feb; 93(2):130-4. PubMed ID: 7479230
[TBL] [Abstract][Full Text] [Related]
2. Topotecan, Ara-C, cisplatin and prednisolone (TOPOSHAP) for patients with refractory and relapsing lymphomas: results of a phase I trial.
Coutinho F; Manhani AR; Velasquez WS; Del Giglio A
Acta Haematol; 2004; 112(3):121-5. PubMed ID: 15345892
[TBL] [Abstract][Full Text] [Related]
3. Treatment of refractory non-Hodgkin's lymphomas of unfavorable histology with teniposide, cytarabine, and cisplatin.
Tseng A; Jacobs C; Coleman CN; Horning SJ; Lewis BJ; Rosenberg SA
Cancer Treat Rep; 1987 Jun; 71(6):659-60. PubMed ID: 3581106
[No Abstract] [Full Text] [Related]
4. Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma.
Carella AM; Cavaliere M; Lerma E; Ferrara R; Tedeschi L; Romanelli A; Vinci M; Pinotti G; Lambelet P; Loni C; Verdiani S; De Stefano F; Valbonesi M; Corsetti MT
J Clin Oncol; 2000 Dec; 18(23):3918-24. PubMed ID: 11099321
[TBL] [Abstract][Full Text] [Related]
5. Cytarabine, cisplatin, and etoposide chemotherapy for refractory non-Hodgkin's lymphoma.
O'Donnell MR; Forman SJ; Levine AM; Territo M; Farbstein MJ; Fahey JL; Gill P; Lazar G; Nademanee A; Neely S
Cancer Treat Rep; 1987 Feb; 71(2):187-9. PubMed ID: 3802114
[TBL] [Abstract][Full Text] [Related]
6. Modified outpatient dexamethazone, cytarabine and cisplatin regimen may lead to high response rates and low toxicity in lymphoma.
Kanat O; Ozet A; Ataergin S; Arpaci F; Kuzhan O; Komurcu S; Ozturk B; Ozturk M
Med Princ Pract; 2010; 19(5):344-7. PubMed ID: 20639655
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of treatment of children and adolescents with recurrent non-Hodgkin's lymphoma and Hodgkin's disease with dexamethasone, etoposide, cisplatin, cytarabine, and l-asparaginase, maintenance chemotherapy, and transplantation: Children's Cancer Group Study CCG-5912.
Kobrinsky NL; Sposto R; Shah NR; Anderson JR; DeLaat C; Morse M; Warkentin P; Gilchrist GS; Cohen MD; Shina D; Meadows AT
J Clin Oncol; 2001 May; 19(9):2390-6. PubMed ID: 11331317
[TBL] [Abstract][Full Text] [Related]
8. Advances in chemotherapy for Hodgkin's and non-Hodgkin's lymphomas.
Semin Hematol; 1988 Apr; 25(2 Suppl 2):1-73. PubMed ID: 3399906
[No Abstract] [Full Text] [Related]
9. DHAP treatment: results of 18 patients with refractory or recurrent non Hodgkin's lymphoma.
Martelli M; Cimino G; Gastaldi R; Mantovani L; Sgadari C; Amadori S; Guglielmi C
Haematologica; 1990; 75(2):194-5. PubMed ID: 2358209
[No Abstract] [Full Text] [Related]
10. Chemotherapy-induced hypothermia in non-Hodgkin's lymphoma.
Manoharan A; Lewis CR
Cancer Treat Rep; 1986 Nov; 70(11):1347. PubMed ID: 3768881
[No Abstract] [Full Text] [Related]
11. Phase I/II study of high-dose cyclophosphamide, etoposide and cisplatin followed by autologous bone marrow or peripheral blood stem cell transplantation in patients with poor prognosis Hodgkin's disease or non-Hodgkin's lymphoma.
Klumpp TR; Mangan KF; Glenn LD; Malaspina DR; Cropper T; Mullaney M; Macdonald JS
Bone Marrow Transplant; 1993 Oct; 12(4):337-45. PubMed ID: 7506091
[TBL] [Abstract][Full Text] [Related]
12. Treatment of advanced refractory lymphomas with a combination of carmustine, bleomycin, teniposide, dexamethasone, and cisplatin (the BBVDD regimen). An ECOG pilot study.
Spiers AS; Weens JH; Rowe JM; Smith TJ; Horton J; Gordon LI; Glick JH
Am J Clin Oncol; 1991 Dec; 14(6):519-25. PubMed ID: 1720279
[TBL] [Abstract][Full Text] [Related]
13. [Malignant lymphoma and adult T-cell leukemia-lymphoma].
Kato K
Rinsho Ketsueki; 2014 Feb; 55(2):191-200. PubMed ID: 24598187
[No Abstract] [Full Text] [Related]
14. Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma.
Vose JM; Crump M; Lazarus H; Emmanouilides C; Schenkein D; Moore J; Frankel S; Flinn I; Lovelace W; Hackett J; Liang BC
J Clin Oncol; 2003 Feb; 21(3):514-9. PubMed ID: 12560443
[TBL] [Abstract][Full Text] [Related]
15. ESHAP chemotherapy for relapsed/refractory non-Hodgkin's lymphoma.
Sweetenham JW; Johnson PW
J Clin Oncol; 1994 Dec; 12(12):2766. PubMed ID: 7989954
[No Abstract] [Full Text] [Related]
16. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.
Abali H; Urün Y; Oksüzoğlu B; Budakoğlu B; Yildirim N; Güler T; Ozet G; Zengin N
Cancer Invest; 2008 May; 26(4):401-6. PubMed ID: 18443961
[TBL] [Abstract][Full Text] [Related]
17. [Post-chemotherapy hypothermia in non-Hodgkin's lymphoma].
Guedea F; Domingo P; Ris J
Med Clin (Barc); 1987 Feb; 88(6):257. PubMed ID: 3561065
[No Abstract] [Full Text] [Related]
18. Combination chemotherapy with mitoguazon, ifosfamide, MTX, etoposide (MIME) and G-CSF can efficiently mobilize PBPC in patients with Hodgkin's and non-Hodgkin's lymphoma.
Aurlien E; Holte H; Pharo A; Kvaløy S; Jakobsen E; Smeland EB; Kvalheim G
Bone Marrow Transplant; 1998 May; 21(9):873-8. PubMed ID: 9613778
[TBL] [Abstract][Full Text] [Related]
19. Ifosfamide, epirubicin and etoposide (IEV) therapy in relapsed and refractory high-grade non-Hodgkin's lymphoma and Hodgkin's disease.
Zinzani PL; Barbieri E; Visani G; Gherlinzoni F; Perini F; Neri S; Bendandi M; Ammendolia I; Salvucci M; Babini L
Haematologica; 1994; 79(6):508-12. PubMed ID: 7534744
[TBL] [Abstract][Full Text] [Related]
20. [Efficacy of DACE regimen on relapsed and refractory non-Hodgkin's lymphoma].
Zhang MZ; Zang WP; Song M; Geng L; Li X; Wang RL
Ai Zheng; 2008 Apr; 27(4):435-7. PubMed ID: 18423133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
